WHO (2014) World Health Statistics 2014. https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/
Kumar V, Abbas AK, Aster JC (2013) Robbins basic pathology. Elsevier Health Sciences Philadelphia
Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT, De K, Sun L-Z (2010) Doxorubicin in combination with a small TGFβ inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One 5(4). https://doi.org/10.1371/journal.pone.0010365
Tam K (2013) The roles of doxorubicin in hepatocellular carcinoma. ADMET and DMPK 1(3):29–44. https://doi.org/10.5599/admet.1.3.7
Article
Google Scholar
Chatterjee K, Zhang J, Honbo N, Karliner JS (2010) Doxorubicin cardiomyopathy. Cardiology 115(2):155–162. https://doi.org/10.1159/000265166
Article
CAS
PubMed
Google Scholar
Pugazhendhi A, Edison T, Velmurugan BK, Jacob JA, Karuppusamy I (2018) Toxicity of doxorubicin (Dox) to different experimental organ systems. Life Sci 200:26–30. https://doi.org/10.1016/j.lfs.2018.03.023
Lovitt CJ, Shelper TB, Avery VM (2018) Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins. BMC Cancer 18(1):41. https://doi.org/10.1186/s12885-017-3953-6
Erlund I (2004) Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutrition Research 24(10):851–874. https://doi.org/10.1016/j.nutres.2004.07.005
Article
CAS
Google Scholar
Sivagami G, Vinothkumar R, Bernini R, Preethy CP, Riyasdeen A, Akbarsha MA, Menon VP, Nalini N (2012) Role of hesperetin (a natural flavonoid) and its analogue on apoptosis in HT-29 human colon adenocarcinoma cell line--a comparative study. Food Chem Toxicol 50(3-4):660–671. https://doi.org/10.1016/j.fct.2011.11.038
Article
CAS
PubMed
Google Scholar
Yang Y, Wolfram J, Shen H, Fang X, Ferrari M (2012) Hesperetin: an inhibitor of the transforming growth factor-β (TGF-β) signaling pathway. Eur J Med Chem 58:390–395. https://doi.org/10.1016/j.ejmech.2012.10.028
Article
CAS
PubMed
PubMed Central
Google Scholar
Zarebczan B, Pinchot SN, Kunnimalaiyaan M, Chen H (2011) Hesperetin, a potential therapy for carcinoid cancer. Am J Surg 201(3):329–332; discussion 333. https://doi.org/10.1016/j.amjsurg.2010.08.018
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang Y, Liu S, Dong W, Qu X, Huang C, Yan T, Du J (2019) Combination of hesperetin and platinum enhances anticancer effect on lung adenocarcinoma. Biomedicine and Pharmacotherapy 113:108779. https://doi.org/10.1016/j.biopha.2019.108779
Sarmoko, Putri DPP, Susidarti RA, Nugroho AE, Meiyanto E (2014) Increasing sensitivity of MCF-7/DOX cells towards doxorubicin by hesperetin through suppression of P-glycoprotein expression. Indonesian J Pharm 25(2):84–90
Alshatwi AA, Ramesh E, Periasamy VS, Subash-Babu P (2013) The apoptotic effect of hesperetin on human cervical cancer cells is mediated through cell cycle arrest, death receptor, and mitochondrial pathways. Fundam Clin Pharmacol 27(6):581–592. https://doi.org/10.1111/j.1472-8206.2012.01061.x
Article
CAS
PubMed
Google Scholar
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1-2):55–63
Article
CAS
Google Scholar
Reynolds CP, Maurer BJ (2005) Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol Med 110:173–183. https://doi.org/10.1385/1-59259-869-2:173
Article
CAS
PubMed
Google Scholar
Chou T-C (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440–446. https://doi.org/10.1158/0008-5472.can-09-1947
Article
CAS
PubMed
Google Scholar
Jenie RI, Handayani S, Susidarti RA, Udin LZ, Meiyanto E (2018) The cytotoxic and antimigratory activity of Brazilin-Doxorubicin on MCF-7/HER2 cells. Adv Pharm Bull 8(3):507–516. https://doi.org/10.15171/apb.2018.059
Article
CAS
PubMed
PubMed Central
Google Scholar
Putri H, Jenie RI, Handayani S, Kastian RF, Meiyanto E (2016) Combination of potassium pentagamavunon-0 and doxorubicin induces apoptosis and cell cycle arrest and inhibits metastasis in breast cancer cells. Asian Pac J Cancer Prev 17(5):2683–2688
PubMed
Google Scholar
Wong CC, Cheng KW, Rigas B (2012) Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents. J Pharmacol Exp Ther 341(3):572–578. https://doi.org/10.1124/jpet.112.191957
Article
CAS
PubMed
PubMed Central
Google Scholar
de Oliveira JMP F, Santos C, Fernandes E (2019) Therapeutic potential of hesperidin and its aglycone hesperetin: cell cycle regulation and apoptosis induction in cancer models. Phytomed 152887. https://doi.org/10.1016/j.phymed.2019.152887
Lee D-H, Park K-I, Park H-S, Kang S-R, Nagappan A, Kim J-A, Kim E-H, Lee W-S, Hah Y-S, Chung H-J (2012) Flavonoids isolated from Korea Citrus aurantium L. induce G2/M phase arrest and apoptosis in human gastric cancer AGS cells. Evid Based Complement Alternat Med 2012:515901
PubMed
Google Scholar
Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411(6835):342
Article
CAS
Google Scholar
Swift LP, Cutts SM, Nudelman A, Levovich I, Rephaeli A, Phillips DR (2008) The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. Cancer Chemother Pharmacol 61(5):739–749. https://doi.org/10.1007/s00280-007-0528-2
Article
CAS
PubMed
Google Scholar
Mc Gee MM (2015) Targeting the mitotic catastrophe signaling pathway in cancer. Mediators Inflamm 2015:146282–146282. https://doi.org/10.1155/2015/146282
Article
CAS
PubMed
PubMed Central
Google Scholar
Elango R, Athinarayanan J, Subbarayan VP, Lei DK, Alshatwi AA (2018) Hesperetin induces an apoptosis-triggered extrinsic pathway and a p53-independent pathway in human lung cancer H522 cells. J Asian Nat Prod Res 20(6):559–569
Article
CAS
Google Scholar
Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, Willbanks A, Sarkar S (2015) EMT and tumor metastasis. Clin Transl Med 4(1):6. https://doi.org/10.1186/s40169-015-0048-3
Kalluri R (2009) EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Inves 119(6):1417–1419
Article
CAS
Google Scholar
Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi J, Nevo J, Gjerdrum C, Tiron C, Lorens J, Ivaska J (2011) Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 30(12):1436
Article
CAS
Google Scholar
Kopp F, Oak PS, Wagner E, Roidl A (2012) miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PLoS One 7(11):e50469
Article
CAS
Google Scholar
Amalina ND, Nurhayati IP, Meiyanto E (2017) Doxorubicin induces lamellipodia formation and cell migration. Indones J Cancer Chemoprevention 8(2):61–67
Article
Google Scholar
Krause M, Gautreau A (2014) Steering cell migration: lamellipodium dynamics and the regulation of directional persistence. Nat Rev Mol Cell Biol 15(9):577
Article
CAS
Google Scholar
Yarrow JC, Perlman ZE, Westwood NJ, Mitchison TJ (2004) A high-throughput cell migration assay using scratch wound healing, a comparison of image-based readout methods. BMC Biotechnol 4(1):21
Article
Google Scholar
Boudreau HE, Casterline BW, Rada B, Korzeniowska A, Leto TL (2012) Nox4 involvement in TGF-beta and SMAD3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells. Free Radic Biol Med 53(7):1489–1499. https://doi.org/10.1016/j.freeradbiomed.2012.06.016
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang X, Meng Q, Qi F, Yang Q (2014) Blocking TGF-ß inhibits breast cancer cell invasiveness via ERK/S100A4 signal. Eur Rev Med Pharmacol Sci 18:3844–3853
CAS
PubMed
Google Scholar
Chen Y-Y, Lu H-F, Hsu S-C, Kuo C-L, Chang S-J, Lin J-J, Wu P-P, Liu J-Y, Lee C-H, Chung J-G, Chang J-B (2015) Bufalin inhibits migration and invasion in human hepatocellular carcinoma SK-Hep1 cells through the inhibitions of NF-kB and matrix metalloproteinase-2/-9-signaling pathways. Environ Toxicol 30(1):74–82. https://doi.org/10.1002/tox.21896
Article
CAS
PubMed
Google Scholar
Gastonguay A, Berg T, Hauser AD, Schuld N, Lorimer E, Williams CL (2012) The role of Rac1 in the regulation of NF-kB activity, cell proliferation, and cell migration in non-small cell lung carcinoma. Cancer Biol Ther 13(8):647–656. https://doi.org/10.4161/cbt.20082
Article
CAS
PubMed
PubMed Central
Google Scholar
Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, La Verde N, Caroti C, Treilleux I, Ruggiero A, Perrone G, Addeo R, Clezardin P, Muda AO, Tonini G (2011) Receptor Activator of NF-kB (RANK) Expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One 6(4):e19234. https://doi.org/10.1371/journal.pone.0019234
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang B, Li L, Jin P, Li M, Li J (2017) Hesperetin protects against inflammatory response and cardiac fibrosis in postmyocardial infarction mice by inhibiting nuclear factor κB signaling pathway. Exp Ther Med 14(3):2255–2260. https://doi.org/10.3892/etm.2017.4729
Article
CAS
PubMed
PubMed Central
Google Scholar
Yin Y, Xu Y, Ma H, Tian X (2017) Hesperetin ameliorates cardiac inflammation and cardiac fibrosis in streptozotocin-induced diabetic rats by inhibiting NF-κB signaling pathway. Studies 14:16
Tsai C-H, Hsieh Y-S, Yang S-F, Chou M-Y, Chang Y-C (2003) Matrix metalloproteinase 2 and matrix metalloproteinase 9 expression in human oral squamous cell carcinoma and the effect of protein kinase C inhibitors: preliminary observations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95(6):710–716. https://doi.org/10.1067/moe.2003.121
Article
PubMed
Google Scholar